Vaxart announced that it has appointed Phillip Lee as its Chief Financial Officer, CFO, effective immediately. Most recently, Lee was CFO and Chief Operating Officer at Clover Biopharmaceuticals and prior to that held finance leadership positions at several biotechnology companies.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VXRT:
- Vaxart price target lowered to $1.50 from $6 at B. Riley
- Vaxart announces collaborative funding for study on Novovirus vaccine candidate
- Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
- Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
